These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18337833)

  • 1. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.
    Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833
    [No Abstract]   [Full Text] [Related]  

  • 2. A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection.
    Wang H; Presland RB; Piepkorn M
    Arch Dermatol; 2005 Feb; 141(2):177-80. PubMed ID: 15724013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.
    Rezze GG; Leon A; Silva DC; Neves RI; Molina GC; Carraro DM; Landman G; Duprat JP
    Acta Derm Venereol; 2012 Jan; 92(1):98-9. PubMed ID: 21710107
    [No Abstract]   [Full Text] [Related]  

  • 4. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal assessment of the nevus phenotype in a melanoma kindred.
    Florell SR; Meyer LJ; Boucher KM; Porter-Gill PA; Hart M; Erickson J; Cannon-Albright LA; Pershing LK; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2004 Sep; 123(3):576-82. PubMed ID: 15304099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma.
    Tsao H; Sober AJ; Niendorf KB; Zembowicz A
    N Engl J Med; 2004 Feb; 350(9):924-32. PubMed ID: 14985491
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective loss of wild-type p16(INK4a) expression in human nevi.
    Scurr LL; McKenzie HA; Becker TM; Irvine M; Lai K; Mann GJ; Scolyer RA; Kefford RF; Rizos H
    J Invest Dermatol; 2011 Nov; 131(11):2329-32. PubMed ID: 21734716
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
    Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
    Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A murine model for the development of melanocytic nevi and their progression to melanoma.
    Nasti TH; Cochran JB; Tsuruta Y; Yusuf N; McKay KM; Athar M; Timares L; Elmets CA
    Mol Carcinog; 2016 May; 55(5):646-58. PubMed ID: 25788145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
    de Torre C; Martínez-Escribano J
    Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations.
    de Jel MM; Engelmann JC; Kunz M; Schiffner S; Kuphal S; Bosserhoff AK
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):678-80. PubMed ID: 24661573
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous topographic profiles of kinetic and cell cycle regulator microsatellites in atypical (dysplastic) melanocytic nevi.
    Husain EA; Mein C; Pozo L; Blanes A; Diaz-Cano SJ
    Mod Pathol; 2011 Apr; 24(4):471-86. PubMed ID: 21336261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations.
    Bishop JA; Wachsmuth RC; Harland M; Bataille V; Pinney E; MacK P; Baglietto L; Cuzick J; Bishop DT
    J Invest Dermatol; 2000 Jan; 114(1):28-33. PubMed ID: 10620111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
    Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
    Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A novel mutation in a patient from a melanoma-prone family.
    Grammatico P; Binni F; Eibenschutz L; De Bernardo C; Grammatico B; Rinaldi R; De Simone P; Catricalà C
    Melanoma Res; 2001 Oct; 11(5):447-9. PubMed ID: 11595880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.